30 results
8-K
EX-99.1
CALC
CalciMedica Inc
13 May 24
CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates
4:39pm
calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported
8-K
EX-99.1
CALC
CalciMedica Inc
28 Mar 24
CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates
7:15am
for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the year ended December 31, 2023.
“Over the course … aberrant activation of these channels may play a key role in the pathobiology of acute and chronic inflammatory syndromes. Auxora is currently being
8-K
EX-99.1
CALC
CalciMedica Inc
13 Feb 24
Regulation FD Disclosure
5:30pm
Differentiated Pipeline in Acute and Chronic Inflammatory and Immunologic Diseases Phase of Development 1 Program Indication Anticipated Milestones … Chronic Disease (Oral) CM6336 Chronic Pancreatitis Submit IND in 2H24 Submit IND in 2H24 CM6336 Rheumatoid Arthritis 4 1) All Auxora programs are IV
8-K
CALC
CalciMedica Inc
13 Feb 24
Regulation FD Disclosure
5:30pm
% or greater risk for death while hospitalized and in the 90 days after discharge. Survivors of severe AKI may develop or progress to chronic kidney … to the FDA in the second half of 2024 for the Company’s oral candidate (CM6336) for the treatment of chronic pancreatitis; and
the Company plans to submit
8-K/A
EX-99.1
20f2biz ogctyuzhyug0
24 Jan 24
CalciMedica Announces Private Placement of up to Approximately $55 Million
6:09am
8-K
EX-99.1
khzah8lai3k5zyzig5h2
22 Jan 24
CalciMedica Announces Private Placement of up to Approximately $55 Million
8:42am
8-K
EX-99.1
4l7hl97kasif2 w5
9 Nov 23
CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
7:05am
8-K
EX-99.1
6b3ys
2 Nov 23
CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition
9:26am
8-K
EX-99.1
btli5w6 72a
11 Aug 23
Other Events
4:28pm
8-K
EX-99.1
p9pqs
10 Aug 23
CalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
5:02pm
8-K
EX-99.1
aarsxr4byu9z 0616w
15 Jun 23
Regulation FD Disclosure
6:15am
8-K
EX-99.1
3lk3tplq1l2jri5
15 May 23
CalciMedica Reports First Quarter 2023 Financial Results and Provides Clinical & Corporate Updates
8:14am
PREM14A
a7m0 xlltktx4v
14 Dec 22
Preliminary proxy related to merger
5:23pm
DEFA14A
w9ch3kd7 edw8rpp
22 Nov 22
Additional proxy soliciting materials
7:57am